| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights |
| 10 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more
Introductory. Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of (i) 58,747,235 shares of its common stock... |
| 06 Nov 2026 | 424B5 |
| 06 Nov 2026 | FWP |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Inovio Pharmaceuticals, Inc. (the “Company”) is providing the following financial information. As of September 30, 2026, the Company estimates that its cash, cash equivalents and short-term investments were approximately $48.4 million. |
| 05 Nov 2026 | 424B5 |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 02 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
FDA Accelerated Approval of VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Investor Call November 2, 2026 Exhibit 99.2 |
| 06 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
This Amendment (the “Amendment”) to the Amended and Restated Bylaws (the “Bylaws”) of Inovio Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), is made effective as of the date first above written in accordance with Artic... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 31 Jul 2026 | SCHEDULE 13G |
| 31 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Warrants to Purchase Up to 42,105,264 Shares of Common Stock (or Pre-Funded Warrants in lieu thereof) |
Loading...